New Zealand Phenoxyethanol Market to Reach US$ 8.66 Million by 2031, Rising at a CAGR of 5.8%, Report by CoherentMI
July 26, 2024 07:05 ET
|
CMI
Burlingame, July 26, 2024 (GLOBE NEWSWIRE) -- According to CoherentMI, New Zealand Phenoxyethanol Market was valued at US$ 5.87 Million in 2024 and is anticipated to reach a value of US$ 8.66...
Global Sales of Chaga Mushrooms Have Been Forecasted to Reach US$ 2.1 Million by 2034 | Fact.MR Report
July 25, 2024 01:00 ET
|
FACT.MR
Rockville, MD., July 25, 2024 (GLOBE NEWSWIRE) -- According to the latest research report released by Fact.MR, the global Chaga Mushroom Market is projected to reach a size of US$ 1.05 billion in...
Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024
July 23, 2024 16:05 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, July 23, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report second...
Sanofi: Informations relatives au nombre de droits de vote et d'actions – Juin 2024
July 22, 2024 16:05 ET
|
Sanofi - Aventis Groupe
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés...
Sanofi: Information concerning the total number of voting rights and shares – June 2024
July 22, 2024 16:05 ET
|
Sanofi - Aventis Groupe
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement...
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe
July 22, 2024 06:30 ET
|
Alvotech
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe
Paratek Pharmaceuticals Announces Positive Top-line Efficacy and Safety Data from Post-Marketing Study of NUZYRA® (omadacycline) for Patients with Moderate to Severe Community-Acquired Bacterial Pneumonia
July 18, 2024 07:30 ET
|
Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals Announces Positive Top-line Efficacy and Safety Data from Post-Marketing Study of NUZYRA®
Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of Assets
July 17, 2024 18:45 ET
|
Nufarm
Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina.
Industrial Roboverse in F&B and Pharmaceutical Markets, 2024 Research - Opportunities in Collaborative Robots, Warehouse Automation, and AI-driven Robots
July 17, 2024 05:36 ET
|
Research and Markets
Dublin, July 17, 2024 (GLOBE NEWSWIRE) -- The "Industrial Roboverse Growth Opportunities in the F&B and Pharmaceutical Industries" report has been added to ResearchAndMarkets.com's...
Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
July 16, 2024 16:01 ET
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million